Measles vaccine makers report shortages in Canada as cases rise – National

Two companies that supply measles vaccines to Canada say they are running short on doses.

The disclosure comes as the highly contagious infection is spreading across the country and with health authorities strongly advising Canadians to be fully vaccinated against the disease, especially before travelling.

Pharmaceutical giants Merck and GlaxoSmithKline (GSK) posted reports to Canada’s drug shortage website showing they are experiencing shortages for their MMR vaccines used to vaccinate against measles, mumps and rubella, with remaining doses reserved for public immunization programs.

The companies both cite “demand-increase for the drug” as the reason why. Merck’s posting shows remaining doses of its MMR II vaccine are “reserved for the public immunization program.” GlaxoSmithKline’s states the same for its Priorix shot, saying “supply (is) unavailable in the private market.”

Merck’s filing shows the company expects the shortage to end in nearly a month on April 19. GlaxoSmithKline’s estimated end date is “unknown.”

Story continues below advertisement

Merck also reported an anticipated shortage for its MMRV jab ProQuad, which also inoculates against varicella virus as well as measles, from March 22 until April 19.


Click to play video: 'Concerns of measles outbreak growing during March break'


Concerns of measles outbreak growing during March break


The reduction likely only affects people seeking to get another dose ahead of travelling though the shortages come as measles has been spreading in Canada.

“It’s that extra supply that we’re now getting for people who are saying: ‘Well, I’m going to Europe and I know there’s a lot of measles in Europe. And gosh, I can’t remember, did I get a second shot, did I not?,’”Dr. Gerald Evans, the division chair of infectious diseases at Queen’s University, told Global News.

“One of the groups of people that we’re very concerned about are adults now who were born in the 1970s,” he said. He notes that’s because people born before that may have already caught measles and survived, giving them immunity, and because people born after likely have two shots, making them fully vaccinated.

Story continues below advertisement

The federal government declared it eliminated from Canada in 1998 after an immunization campaign, but last week Public Health Ontario said there were more confirmed cases in 2024 than in all of last year, rising from seven in 2023 to eight as of March 13. Quebec has reported 29 cases as of March 20. Other provinces including Saskatchewan and British Columbia have also reported infections.


The latest health and medical news
emailed to you every Sunday.


The latest health and medical news
emailed to you every Sunday.

Evans said Canada has always seen the occasional travel-related case because people not fully vaccinated will contract it while abroad.

What the country is seeing this year, he said, is the result of a “marked reduction” of measles vaccinations, especially of children.

“A lot of that is due to the unfortunate spin-off that we had from COVID with the anti-vaccination groups taking on the COVID vaccines,” he said.

Evans said the spread now among people who haven’t travelled shows “the virus is sneakily kind of working its way into the population,” which “really creates a circumstance where we become worried that we’re now going to begin to see outbreaks of measles.”

But because of high Canadian inoculation rates, he said it’s not likely Canadians will have to worry about excessive public health measures.

Two vaccines doses provide nearly 100 per cent efficacy, according to Health Canada.

Story continues below advertisement


Click to play video: 'Breaking down the measles disease and how to protect yourself'


Breaking down the measles disease and how to protect yourself


The vaccine is administered as a two-shot series, with the first shot given at around 12 to 15 months of age and second shot at 18 months or between ages five and six years (before your child starts school).

The World Health Organization said COVID-19 disrupted many vaccinations globally.

On March 19, the WHO director of immunization Kate O’Brien said it is “really critical” to catch up.

More than 50 countries reported “large and disruptive” measles outbreaks in the past year, which is twice as many as the year before.

While measles can cause rashes and flu-like symptoms, Evans stressed it is not a benign illness, saying that “about 1 in 1,000 [people infected with] measles will die, and they’ll die from inflammation of the brain.” Others can suffer long-term health effects, he adds.

Story continues below advertisement

And he said it is so infectious that one person with measles can infect 18 susceptible people, compared to COVID-19’s three or four.

“Measles is one of the most highly communicable infectious diseases, and can very easily spread to other people if they are susceptible,” Health Canada previously told Global News.

Dr. Allen Grill, the chief of family medicine at Markham Stouffville Hospital, outside Toronto, said local and provincial public health authorities reassured him they have enough supplies.

“We aren’t seeing those shortages in our office. And I haven’t heard of it being in a problem among my colleagues, at least in my region and in York region,” he said.


Click to play video: 'Spring travel could bring measles outbreak, Canada’s top doctor says'


Spring travel could bring measles outbreak, Canada’s top doctor says


He said they’re focusing mainly on kids who fell behind in vaccinations during the pandemic and people who aren’t sure if they have two doses, which can be determined with a blood test.

Story continues below advertisement

In a statement to Global News Thursday, Merck said it is aware of the shortage and is working to “provide a consistent supply of (its measles vaccines) in a timely manner.”

“From a global perspective, current demand exceeds available capacity and we are prioritizing our existing commitments,” GSK said  in a statement.

“MMR vaccines are complex, and the lead time makes it challenging to scale up quickly when an urgent need arises. We expect this situation to continue throughout 2024 and 2025,” though GSK said it continues to meet the public market demand for Priorix.

Health Canada did not respond to a request for comment by deadline.

— with files from Global News’ Katie Dangerfield, Gabby Rodrigues and Katherine Ward, Reuters’ Jennifer Rigby and The Associated Press

&copy 2024 Global News, a division of Corus Entertainment Inc.

FOLLOW US ON GOOGLE NEWS

Read original article here

Denial of responsibility! Swift Telecast is an automatic aggregator of the all world’s media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials, please contact us by email – swifttelecast.com. The content will be deleted within 24 hours.

Leave a Comment